Sidley Represents Clear Labs in Its US$30 Million Series D Financing
1/17/2025
Related Professionals
Related Capabilities
SERVICES AND INDUSTRIES
Stay Up To Date
Sidley represented Clear Labs, a provider of fully automated, next-generation sequencing platforms for turnkey diagnostics, in its US$30 million Series D financing. The round was led by a strategic investor, along with participation from existing investors, including Counterpoint Global (Morgan Stanley), Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, and funds and accounts advised by T. Rowe Price Associates, Inc.
The Sidley team was led by Carlton Fleming (Emerging Companies and Venture Capital) and included BinQuan Zhuang, Ph.D. (M&A), Daniel Wei (Emerging Companies and Venture Capital), and Benjamin Farkas (Securities Enforcement and Regulatory).
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.
You have successfully set your edition to Asia Pacific. Would you like to make this selection your default edition?
*Selecting a default edition will set a cookie.
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.